BiomX Q1 net loss $7.7M; cash $21.2M; BX004 Phase 2b topline Q1 2026

BiomX Inc.

2025-Q1 EPS reported $0.33 vs consensus -$6.98 ▲ beat (+104.7%)

Net loss of $7.7M for Q1 2025, compared to $17.3M in Q1 2024; R&D expenses rose to $5.3M from $4.1M.
Cash and restricted cash $21.2M as of March 31, 2025; expects runway into Q1 2026.
Positive Phase 2 results for BX211 in diabetic foot osteomyelitis announced March 2025; planning Phase 2/3 trial pending FDA feedback.
BX004 Phase 2b in cystic fibrosis on track to report topline results in Q1 2026; regulatory discussions expected H2 2025.
Shareholders approved exercise of warrants from $12M February 2025 financings in April 2025, extending operational runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.